INTRODUCTION
Psoriasis is a chronic relapsing immune-mediated disease affecting around 125 million people worldwide.1Plaque psoriasis is the commonest variant that accounts for 90% of psoriasis cases.2 Clinically, Plaque psoriasis is characterized by sharply demarcated red, scaly lesions with desquamation.1With the further understanding of the pathogenesis of psoriasis, targeted biologics are more and more widely used as first-line agents in the treatment of moderate and severe psoriasis, and play a positive role in the treatment of refractory and special types of psoriasis. 3 4Howeve,topical medications is still the most commonly used treatment for mild to moderate psoriasis and all patients can benefit from extensive application of emollients.3,5Up to now,only a few meta-analysis studies have compared the efficacy of different topical therapies for plaque psoriasis.6-10To date, a large number of randomized controlled trials have studied the efficacy and safety of some novel topical drugs,such as aryl hydrocarbon receptor (AhR) inhibitors(tapinarof, benvitimod), phosphodiesterase type 4 (PDE-4) inhibitors(roflumilast) and janus kinase-signal transducer and activator of transcription(JAK-STAT) Inhibitors(tofacitinib, ruxolitinib) and proformed better efficacy.
For completeness,we report an overview of all randomized controlled trials of 10 topical medicine for the treatment of plaque psoriasis and updated the NMA and based on hierarchical cluster analyses to evaluate the short-term topical teatment efficacy,safety and tolerability. It is hoped that, to some extent,these results can provide information for doctors when choosing therapeutic in clinic.